NCT02131155 - LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 17, 2014

Primary Completion Date

August 22, 2016

Study Completion Date

August 22, 2016

Conditions

Head and Neck Neoplasms

Interventions

DRUG

Placebo

Once daily

DRUG

Afatinib

Once daily

Trial Locations (17)

1200.162.86010 Boehringer Ingelheim Investigational Site, Beijing

1200.162.86012 Boehringer Ingelheim Investigational Site, Beijing

1200.162.86019 Boehringer Ingelheim Investigational Site, Changchun

1200.162.86007 Boehringer Ingelheim Investigational Site, Chengdu

1200.162.86017 Boehringer Ingelheim Investigational Site, Fuzhou

1200.162.86005 Boehringer Ingelheim Investigational Site, Guangzhou

1200.162.86003 Boehringer Ingelheim Investigational Site, Hangzhou

1200.162.86013 Boehringer Ingelheim Investigational Site, Jinan

1200.162.86014 Boehringer Ingelheim Investigational Site, Nanning

1200.162.86001 Boehringer Ingelheim Investigational Site, Shanghai

1200.162.86020 Boehringer Ingelheim Investigational Site, Tianjin

1200.162.86004 Boehringer Ingelheim Investigational Site, Wuhan

1200.162.86018 Boehringer Ingelheim Investigational Site, Wuhan

Singapore

1200.162.82001 Boehringer Ingelheim Investigational Site, Seoul

1200.162.82002 Boehringer Ingelheim Investigational Site, Seoul

1200.162.88603 Boehringer Ingelheim Investigational Site, Keelung